Weight Loss Drugs Linked to Lower Dementia Risk in Israeli Study
Translated & summarized from Israel Hayom by baba
An Israeli study of nearly 47,000 patients found that GLP-1 drugs, used for obesity and diabetes, were linked to a 14% lower risk of dementia. The risk reduction was higher for women and those over 65. Researchers suggest these drugs may protect the brain by reducing inflammation and improving insulin response, though further clinical trials are needed to confirm causality.
The story in 5 lines · by baba
- Israeli study links GLP-1 drugs to 14% lower dementia risk in diabetes and obesity patients.
- Women saw a 22% reduced risk, while those 65+ had an 18% lower risk.
- The research involved nearly 47,000 patients over more than a decade.
- Researchers suggest drugs may protect the brain by reducing inflammation and improving insulin response.
- Further clinical trials are needed to confirm a direct causal link.
A new Israeli study suggests that medications used to treat obesity and diabetes, such as Ozempic and Saxenda, may also be associated with a reduced risk of developing dementia. The research, which analyzed data from approximately 47,000 Clalit Health Services patients with type 2 diabetes and obesity over more than a decade, found that individuals treated with GLP-1 receptor agonist drugs had a 14% lower risk of dementia compared to those on other diabetes medications.
The study, published in the European Journal of Internal Medicine, was led by researchers from HaSharon Hospital, Clalit's administration, the Hebrew University, Tel Aviv University, Ariel University, and the Technion. It aimed to explore the connection between diabetes drug treatments and neurodegenerative brain diseases.
The findings indicated a significant link, with the risk reduction being more pronounced in women (22% decrease) and individuals aged 65 and over (18% decrease). However, the researchers emphasized that this study observed a correlation and does not prove that the drugs directly prevent dementia, as it was not a clinical trial.
Professor Dror Dicker, a lead researcher, explained that diabetes and obesity accelerate chronic inflammation, insulin resistance, and vascular damage, all of which can impair brain function and increase dementia risk. He suggested that GLP-1 drugs, beyond their effects on blood sugar and weight, might offer significant brain protection, especially for women and older adults, highlighting the importance of incorporating brain health into personalized treatment strategies.
Dr. Wissam Abu Ahmed, another researcher involved, pointed to potential mechanisms, including the drugs' effects on brain receptors, reduction of neuroinflammation, and improvement of brain cell insulin response. He stressed the need for further clinical trials to confirm causality but noted that the findings open possibilities for broader therapeutic approaches in diabetes and obesity patients.
Mentioned
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 1Right 1